An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline
- PMID: 26177183
- DOI: 10.1164/rccm.201506-1063ST
An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline
Erratum in
-
Erratum: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline.Am J Respir Crit Care Med. 2015 Sep 1;192(5):644. doi: 10.1164/rccm.1925erratum. Am J Respir Crit Care Med. 2015. PMID: 26325160 No abstract available.
Abstract
Background: This document updates the American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin American Thoracic Association guideline on idiopathic pulmonary fibrosis treatment.
Methods: Systematic reviews and, when appropriate, meta-analyses were performed to summarize all available evidence pertinent to our questions. The evidence was assessed using the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach and then discussed by a multidisciplinary panel. Predetermined conflict-of-interest management strategies were applied, and recommendations were formulated, written, and graded exclusively by the nonconflicted panelists.
Results: After considering the confidence in effect estimates, the importance of outcomes studied, desirable and undesirable consequences of treatment, cost, feasibility, acceptability of the intervention, and implications to health equity, recommendations were made for or against specific treatment interventions.
Conclusions: The panel formulated and provided the rationale for recommendations in favor of or against treatment interventions for idiopathic pulmonary fibrosis.
Comment in
-
An Important Step Forward, but Still a Way to Go.Am J Respir Crit Care Med. 2016 Feb 1;193(3):340-1. doi: 10.1164/rccm.201509-1763LE. Am J Respir Crit Care Med. 2016. PMID: 26829426 No abstract available.
-
Idiopathic Pulmonary Fibrosis and Prothrombotic State.Am J Respir Crit Care Med. 2016 Feb 1;193(3):341-2. doi: 10.1164/rccm.201509-1835LE. Am J Respir Crit Care Med. 2016. PMID: 26829427 No abstract available.
-
Reply to "An Important Step Forward, but Still a Way to Go".Am J Respir Crit Care Med. 2016 Feb 1;193(3):342. doi: 10.1164/rccm.201510-2010LE. Am J Respir Crit Care Med. 2016. PMID: 26829428 No abstract available.
-
Reply to "An Important Step Forward, but Still a Way to Go" and "Idiopathic Pulmonary Fibrosis and Prothrombotic State".Am J Respir Crit Care Med. 2016 Feb 1;193(3):343. doi: 10.1164/rccm.201510-2049LE. Am J Respir Crit Care Med. 2016. PMID: 26829429 No abstract available.
-
Can Warfarin Be Used in the Treatment of Pulmonary Embolism in Idiopathic Pulmonary Fibrosis?Am J Respir Crit Care Med. 2016 Apr 1;193(7):810-1. doi: 10.1164/rccm.201511-2267LE. Am J Respir Crit Care Med. 2016. PMID: 27035785 No abstract available.
-
Reply: Can Warfarin Be Used in the Treatment of Pulmonary Embolism in Idiopathic Pulmonary Fibrosis?Am J Respir Crit Care Med. 2016 Apr 1;193(7):811. doi: 10.1164/rccm.201601-0078LE. Am J Respir Crit Care Med. 2016. PMID: 27035786 No abstract available.
-
Can Bisphosphonates Prevent Vitamin K Antagonist Toxicity in Patients with Idiopathic Pulmonary Fibrosis?Am J Respir Crit Care Med. 2017 Jan 15;195(2):269-270. doi: 10.1164/rccm.201605-1074LE. Am J Respir Crit Care Med. 2017. PMID: 28084819 No abstract available.
-
Reply: Can Bisphosphonates Prevent Vitamin K Antagonist Toxicity in Patients with Idiopathic Pulmonary Fibrosis?Am J Respir Crit Care Med. 2017 Jan 15;195(2):271. doi: 10.1164/rccm.201608-1610LE. Am J Respir Crit Care Med. 2017. PMID: 28084827 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical